NasdaqGS:ALMSPharmaceuticals
Assessing Alumis (ALMS) Valuation After Positive Phase 3 Envudeucitinib Psoriasis Results And NDA Plans
Alumis (ALMS) is back in focus after releasing new Phase 3 ONWARD1 and ONWARD2 data on envudeucitinib for moderate to severe plaque psoriasis, alongside plans for a U.S. FDA New Drug Application.
See our latest analysis for Alumis.
The latest Phase 3 psoriasis data arrives after a sharp run up in Alumis’s 90 day share price return of 181.23%, while the year to date share price return of 160.97% and 1 year total shareholder return of 132.54% point to strong momentum even with a 13.12% 30 day...